Article info

Download PDFPDF

Concise report
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

Authors

  1. Correspondence to Dr Tamas Shisha, Sandoz, a Novartis Division, Clinical Development, Industriestrasse 25, 83607 Holzkirchen, Germany; tamas.shisha{at}sandoz.com
View Full Text

Citation

Smolen JS, Cohen SB, Tony H, et al
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

Publication history

  • Received February 9, 2017
  • Revised May 3, 2017
  • Accepted May 4, 2017
  • First published June 21, 2017.
Online issue publication 
August 10, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.